Residents in eastern Congo cling to hope as a new Ebola treatment trial begins

In the heart of Congo's Ebola outbreak, residents are looking to experimental treatments with a mix of hope and urgency as a significant research study commenced in early July. The trial aims to combat the persistent and growing epidemic in the Ituri province.

The research, unfolding at the Ebola treatment center within Bunia's Evangelical Medical Center, began quietly amidst the ongoing efforts to save lives. Ambulances continue to arrive, and healthcare workers, clad in protective gear, move between isolation wards. This outbreak is caused by the Bundibugyo virus, a less common strain for which no specific treatments or vaccines currently exist. The World Health Organization reported on Thursday that the outbreak has already claimed 438 lives among more than 1,400 diagnosed cases.

The WHO announced the enrollment of the first participant in the study, which will assess the effectiveness of the antiviral remdesivir, the experimental antibody treatment MBP134, or a combination of both. Patient survival will be monitored for 28 days post-treatment. This trial is a collaborative effort involving Congo's national biomedical research institute (INRB), Oxford University, Antwerp's Institute of Tropical Medicine, and other international health organizations.

Initially, the trial will focus on confirmed Ebola patients within specialized treatment centers. A subsequent phase is planned to include healthcare workers, close contacts, and others at high risk of infection. Researchers estimate the trial could last from three to six months, depending on the outbreak's progression. For many in Bunia, this research represents a rare glimmer of encouragement amid weeks of mounting fear. "I hope everything moves very quickly so that we can find relief," said Bunia resident Audrey Tengetenge, describing the trials as a "light at the end of the tunnel."

“

I hope everything moves very quickly so that we can find relief. We want nothing more than an end to this very dangerous disease, which continues to bring us grief